Wogonin for the prevention and therapy of cardiac hypertrophy
Cardiac hypertrophy is characterized by a global increase in transcription and protein per cell. Cyclin-dependent kinase 9 (CDK9) is the main driver for transcription and is necessary for hypertrophy in cardiomyocytes. DKFZ scientists have shown that wogonin is a potent inhibitor of CDK9 with no or very low toxicity to normal tissues. Wogonin can be used for preventing cardiac hypertrophy.
Further information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
Media Contact
All latest news from the category: Technology Offerings
Newest articles
CD Laboratory at TU Graz Researches New Semiconductor Materials
Using energy- and resource-saving methods, a research team at the Institute of Inorganic Chemistry at TU Graz aims to produce high-quality doped silicon layers for the electronics and solar industries….
Study on gene regulation with surprising results
Some sequences in the genome cause genes to be switched on or off. Until now, each of these gene switches, or so-called enhancers, was thought to have its own place…
Novel electro-biodiesel
…a more efficient, cleaner alternative to existing alternatives. Vehicles fueled by diesel lead to substantial carbon emissions that are challenging to decarbonize. In 2022, diesel fuel use made up about…